Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: Synthesis, biological evaluation, and modeling of the mode of binding

Journal of Medicinal Chemistry

Volumn 40, Issue 10, 1997, Pages 1519-1529

  Palmer, Brian D ^a   Trumpp Kallmeyer, Susanne ^b   Fry, David W ^b   Nelson, James M ^b   Showalter, H D Hollis ^b   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [(3 BROMOPHENYL)AMINO] 1 [2 (4 MORPHOLINO)ETHYL]PYRROLO[3,2 G]QUINAZOLINE; ADENOSINE TRIPHOSPHATE; AMINO ACID; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; HYDROGEN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; RIBOSE; SULFIDE; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; AUTOPHOSPHORYLATION; BINDING AFFINITY; BINDING SITE; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; IMMUNOAFFINITY CHROMATOGRAPHY; METHYLATION; MODEL; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; BINDING SITES; ENZYME INHIBITORS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; PHOSPHORYLATION; PROTEIN CONFORMATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0030907052     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960789h     Document Type: Article

References (29)

1. El-Zayat A. A. E.; Pingree, T. F.; Mock, P. M.; Clark, G. M.; Otto, R. A.; Von Hoff, D. D. Epidermal growth factor receptor amplification in head and neck cancer. Cancer J. 1991, 4, 375-380.
2. Morishige, K.; Kurachi, H.; Amemiya, K.; Fujita, Y.; Yamamoto, T.; Miyake, A.; Tanizawa, O. Evidence for the involvement of transforming growth factor α and epidermal growth factor receptor automne growth mechanism in primary human ovarian cancers in vitro. Cancer Res. 1991, 51, 5322-5328.
3. Jardines, L.; Weiss, M.; Fowble, B.; Greene, M. Neu (c-erbB-2/ HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 1993, 61, 268-282.
4. Hickey, K.; Grehan, D.; Reid, I. M.; O'Brian, S.; Walsh, T. N.; Hennessy, T. P. J. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 1994, 74, 1693-1698.
5. Delarue, J. C.; Terrier, P.; Terrierlacombe, M. J.; Mouriesse, H.; Gotteland, M.; Maylevin, F. Combined overexpression of c-erbB-2 protein and epidermal growth factor receptor (EGF-r) could be predictive of early and long-term outcome in human breast cancer: a pilot study. Bull. Cancer 1994, 81, 1067-1077.
6. Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambroso, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265, 1093-1095.
7. Ward, W. H. J.; Cook, P. N.; Slater, A. M.; Davies, D. H.; Holdgate, G. A.; Green, L. R. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 1994, 48, 659-666.
8. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H.; Cody, D. R.; McMichael, A.; Fry, D. W. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adeonosine-5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3482-3487.
9. Bridges, A. J., Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A.; Showalter, H. D. H.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 8. An unusually steep structure activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 267-276.
10. Rewcastle, G. W.; Palmer, B. D.; Bridges, A. J.; Showalter, H. D. H.; Nelson, J.; McPherson, A.; Kraker, A. J.; Fry, D. W.; Denny, W. A. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 918-928.
11. Rewcastle, G. W.; Palmer, B. D.; Thompson, A. M.; Bridges, A. J.; Fry, D. J.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 1823-1835.
12. Barker, A. J. Tricyclic derivatives and their use as anti-cancer agents. Patent Application EPO 0 635 507 A1 to Zeneca Ltd., Jan. 21, 1995; Chem. Abstr. 1995, 122, 31545y.
13. Himmelsbach, F.; von Ruden, T.; Dahmann, G.; Metz, T. Pyrimido[5,4-d]pyrimidines, drugs containing these compounds, their use, and process for preparing them. Patent Application PCT/EP95/03482 to Dr. Karl Thomae, GMBH, Sept. 5, 1995; Chem. Abstr. 1996, 124, 303748, 343326.
14. Hudson, A. T.; Vile, S.; Barraclough, P.; Franzmann, K. W.; McKeown, S. C.; Page, M. J. Substituted heteroaromatic compounds and their use in medicine. Patent Application PCT/GB95/ 02202 to The Wellcome Foundation, Sept. 18, 1995; Chem. Abstr. 1996, 125, 114665.
15. Showalter, H. D. H.; Sun, L.; Sercel, A. D.; Winters, R. T.; Denny, W. A.; Palmer, B. D. Concise syntheses of the novel 1H-pyrrolo-[3,2-g]quinazoline ring system and its [2,3-f] angular isomer. J. Org. Chem. 1996, 61, 1155-1158.
16. Thompson, A. M.; Bridges, A. J.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines; a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3780-3788.
17. Zheng, J.; Trafny, E. A.; Knighton, D. R.; Xuong, N.-H.; Taylor, S. S.; Ten Eyck, L. F.; Sowadsky, J. M. 2.2 Å refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Crystallogr. 1993, D49, 362-365.
18. De Bondt, H. L.; Rosenblatt, J.; Jancarik, J.; Jones, H. D.; Morgan, D. O.; Kim, S. H. Crystal structure of cyclin-dependent kinase 2. Nature 1993, 363, 595-602.
19. Zang, F.; Strand, A.; Robbins, D.; Cobb, M. H.; Goldsmith, E. J. Atomic structure of the MAP kinase ERK2 at 2.3 A resolution. Nature 1994, 367, 704-711.
20. Owen, D. J.; Noble, M. E. M.; Carman, E. F.; Papageorgiou, A. C.; Johnson, L. N. Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product. Structure 1995, 3, 467-482.
21. Schulze-Gahmen, U.; Brandsen, J.; Jones, H. D.; Morgan, D. O.; Meijer, L.; Vesely, J.; Kim, S.-H. Multiple modes of ligand recognition: crysral structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomucine and isopentyladenine. Protein 1995, 22, 378-391.
22. Chen, H.; Bioziau, J.; Parker, F.; Maroun, R.; Tocque, B.; Roques, B.; Garbay-Jaureguiberry, C. Synthesis and structure-activity studies of a series of [(hydroxybenzyl)amino]salicylates as inhibitors of EGF receptor-associated tyrosione kinase activity. J. Med. Chem. 1993, 36, 4094-4098.
23. Furet, P.; Caravatti, G.; Lydon, N.; Priestle, J. P.; Sowadski, J. M.; Trinks, U.; Traxler, P. Modelling study of protein kinase inhibitors - binding mode of staurosporine and origin of the selectivity of CGP 52411. J. Comput.-Aided Mol. Des. 1995, 9, 465-472.
24. Traxler, P. M.; Furet, P.; Mett, H.; Buchdunger, E.; Meyer, T.; Lydon, N. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 1996, 39, 2285-2292.
25. LOOK, Molecular Applications Group, Suite T, 445 Sherman Ave, Palo Alto, CA 94306.
26. Knighton, D. R.; Cadena, D. L.; Zheng, J.; Ten Eyck, L. F.; Taylor, S. S.; Sowadski, J. M.; Gill, G. N. Structural features that specify tyrosine kinase activity deduced from homology modeling of the epidermal growth factor receptor. Proc. Natl. Acad. Sci. 1993, 90, 5001-5005.
27. SYBYL molecular modeling software, Tripos E & S, 6548 Clayton Rd, St. Louis, MO 62117.
28. Dewar, M. J. S.; Thiel, W. Ground states of molecules. 38. The MNDO method. Approximation and parameters. J. Am. Chem. Soc. 1977, 99, 4907.
29. Gill, G. N.; Weber, W. Purification of functionally active epidermal growth factor receptor protein using a competitive antagonist monoclonal antibody and competitive elution with epidermal growth factor. Methods Enzymol. 1987, 146, 82-88.